Optimize 340B program compliance and orphan drug spend
Our Orphan Drug Opportunity supplements our Sentinel® technology capabilities, helping to maintain compliance with 340B Orphan Drug Exclusion requirements, uncover cost-effective ways to obtain orphan drugs, and provide ongoing 340B program oversight and maintenance.
Reduce audit risks, meeting 340B program compliance requirements with respect to orphan drug exclusions
Verify that our Sentinel Blacklist Tool contains the most up-to-date list of orphan drugs
Adjust configurations in the Sentinel Blacklist Tool to meet program requirements
Assess active manufacturer contracts for orphan drugs and identify opportunities to optimize purchasing
Negotiate/renegotiate external contracts and agreements with orphan drug manufacturers as necessary
Provide quarterly program review, adjusting orphan drug NDCs in the Sentinel Blacklist Tool and reviewing contracts with manufacturers
Common pain point
Maintaining compliance when it comes to 340B Orphan Drug Exclusion requirements is a challenge that not every system can meet — and negotiating discounts on orphan drugs can often go overlooked.
Our Orphan Drug Opportunity service helps you verify that you have the most up-to-date list of orphan drugs on hand and that they are excluded from 340B. We will also help you evaluate and negotiate existing contracts with pharma manufacturers to optimize orphan drug prices.
Interested in knowing more? Complete the form below to request a free needs assessment and see how together we can optimize your orphan drug compliance and pricing.
